Between May 30 , 2012 , and Dec 30 , 2013 , 1224 patients in UNCOVER-2 were randomly assigned to receive subcutaneous placebo ( n = 168 ) , etanercept ( n = 358 ) , or ixekizumab every 2 weeks ( n = 351 ) or every 4 weeks ( n = 347 ) ; between Aug 11 , 2012 , and Feb 27 , 2014 , 1346 patients in UNCOVER-3 were randomly assigned to receive placebo ( n = 193 ) , etanercept ( n = 382 ) , ixekizumab every 2 weeks ( n = 385 ) , or ixekizumab every 4 weeks ( n = 386 ) .